Drugs in Treatment of Migraine

Migraine is a very frequent and disabling neurological disorder. The current treatment options are old, generally poorly tolerated and not migraine-specific, thereby highlighting the vast unmet need in its management. Advances in the understanding of the pathophysiology of migraine and identification of novel targets have resulted in the development of several acute and preventive treatments. Novel treatments that are emerging target the Calcitonin-Gene-Related Peptide (CGRP) receptor and ligand as well as the 5 hydroxytryptamine (5-HT)1F receptor. The acute treatments being developed include the ditans (5HT-1F receptor agonists) and gepants (small molecule CGRP receptor antagonists). The preventive treatments include gepants and CGRP receptor/ligand monoclonal antibodies. The efficacy, clinical potential, safety and cost-effectiveness of these novel therapeutic agents will be reviewed